mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials

This publication has 32 references indexed in Scilit:

• Human Infection with a Novel Avian-Origin Influenza A (H7N9) Virus
  New England Journal of Medicine, 2013
• Effects of Vaccine Program against Pandemic Influenza A(H1N1) Virus, United States, 2009–2010
  Emerging Infectious Diseases, 2013
• Modeling the Effects of H1N1 Influenza Vaccine Distribution in the United States
  Value in Health, 2011
• DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials
  The Lancet Infectious Diseases, 2011
• AS03_A‐Adjuvanted Influenza A (H1N1) 2009 Vaccine for Adults up to 85 Years of Age
  Clinical Infectious Diseases, 2010
• Relationship between haemagglutination-inhibiting antibody titres and clinical protection against influenza: development and application of a bayesian random-effects model
  BMC Medical Research Methodology, 2010
• Response to a Monovalent 2009 Influenza A (H1N1) Vaccine
  New England Journal of Medicine, 2009
• Quadrivalent Meningococcal Vaccination of Adults: Phase III Comparison of an Investigational Conjugate Vaccine, MenACWY-CRM, with the Licensed Vaccine, Menactra
  Clinical and Vaccine Immunology, 2009
• Immunogenicity and protective efficacy of influenza vaccination
  Virus Research, 2004
• The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses
  Epidemiology and Infection, 1972